Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the ...

Scott joins Kailera from Cerevel Therapeutics where he served as Chief Legal Officer and Corporate Secretary until the company’s acquisition by AbbVie in 2024 ... Corporate Communications and Investor ...

Q3 2024 Earnings Call Transcript November 7, 2024 Ironwood Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & ...

However, as US-China trade relations continue to deteriorate ... including Novartis and Beigene ($2.2 billion), AbbVie and I-Mab ($1.9 billion), and Seagen and RemeGen ($2.4 billion).

Over the twelve months to September 2024, AbbVie recorded an accrual ratio of -0.16. Therefore, its statutory earnings were very significantly less than its free cashflow. Indeed, in the last ...

While certainly a blow, the resulting drop of nearly 10% as I write this appears to be significantly overdone, and I think ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors. However, this came as good news for investors in AbbVie’s peer Bristol Myers ...